Abivax presented 22 abstracts at ECCO 2026 demonstrating obefazimod's anti-fibrotic activity in preclinical models, favorable safety profile comparable to placebo, and rapid symptomatic improvements in ulcerative colitis patients. Biomarker data showed upregulation of miR-124 and reduction of inflammatory cytokines IL-17A and IL-6. The company expects Phase 3 maintenance trial results in Q2 2026 and Phase 2b ENHANCE-CD trial results in Q4 2026.

For investors who missed Eli Lilly's impressive run, two smaller biotech companies offer potential alternatives: Viking Therapeutics is developing VK2735, a weight-loss drug similar to Eli Lilly's Zepbound with phase 3 results expected next year, while Abivax is testing obefazimod for ulcerative colitis with maintenance study results planned for Q2. Both stocks carry high risk but could deliver significant rewards if their clinical trials succeed.

AbbVie, a pharmaceutical giant with strong immunology products like Skyrizi and Rinvoq, is compared against Abivax, an emerging biotech company developing obefazimod for ulcerative colitis. AbbVie offers stability, consistent revenue, and dividend income, making it suitable for risk-averse investors. Abivax presents higher risk but significant upside potential if its drug successfully reaches the market, with possible acquisition prospects.

Abivax stock surged nearly 21% on December 22, 2025, following reports that Eli Lilly is interested in acquiring the France-based biotech company. According to French media, Eli Lilly representatives met with French Treasury officials to discuss regulatory requirements for the acquisition. The interest was likely sparked by Abivax's positive Phase 3 clinical trial results for its ulcerative colitis drug obefazimod. However, the analyst notes that persistent rumors may prevent the deal from commanding a premium price.

Abivax stock surged on market rumors of a potential takeover by Eli Lilly, following impressive clinical trial results for its ulcerative colitis treatment obefazimod.

Abivax reported positive Phase 3 trial results for obefazimod in treating ulcerative colitis, with a 16.4% placebo-adjusted clinical remission rate at Week 8 and no significant safety concerns.

Abivax reported a net loss of €100.8M for the first half of 2025, with increased R&D expenses primarily driven by Crohn's Disease clinical program. The company completed a $747.5M public offering and expects to fund operations into Q4 2027.

The article explores two promising biotech companies, Viking Therapeutics and Recursion Pharmaceuticals, highlighting their innovative approaches in weight loss treatments and AI-driven drug development, respectively.

Abivax has temporarily halted trading of its ordinary shares on Euronext Paris to facilitate its public offering of American Depositary Shares in the United States, with trading expected to resume later the same day.

French biotechnology company Abivax SA reported positive Phase 3 clinical trial results for obefazimod, a treatment for ulcerative colitis, causing its stock to surge over 400% in premarket trading on July 23, 2025.

Abivax held its annual general meeting on June 6, 2025, where shareholders approved the financial statements, compensation policies, and board appointments.

Abivax, a clinical-stage biotechnology company, announced its Q1 2025 financial results. The company's operating loss increased due to higher R&D expenses, particularly for its Crohn's disease program. However, sales and marketing expenses decreased. Abivax's cash position declined, but the company expects to have sufficient funds to finance its operations into Q4 2025.